The GSTM2 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of HeLa cells harboring targeted disruption of the GSTM2 gene. This loss-of-function model is designed to eliminate functional glutathione S-transferase Mu 2 (GSTM2) protein expression, providing a versatile tool for investigating cellular detoxification and stress response pathways. The polyclonal format ensures a heterogeneous knockout background, enabling robust representation of gene-disrupted phenotypes without clonal bias. This product is ideal for studying mechanisms of xenobiotic metabolism and drug resistance in an established human cervical carcinoma context.
HeLa cells are an immortalized human cervical adenocarcinoma cell line that is HPV18-positive, widely utilized in cancer biology and toxicology research. Their rapid proliferation, ease of culture, and extensive characterization make them a standard platform for gene disruption studies. The epithelial origin and malignant phenotype of HeLa cells render them particularly suitable for examining the roles of detoxification enzymes in cancer cell survival and chemotherapeutic sensitivity. The integration of GSTM2 knockout into this background facilitates dissection of glutathione-dependent protective mechanisms against electrophilic and oxidative insults.
GSTM2 encodes a glutathione S-transferase that catalyzes the conjugation of reduced glutathione to electrophilic compounds, facilitating their detoxification and elimination. Its expression is primarily regulated by nuclear factor erythroid 2-related factor 2 (NFE2L2/Nrf2), a transcription factor activated by oxidative stress and electrophilic compounds via dissociation from KEAP1. Upon activation, NFE2L2 binds to antioxidant response elements (AREs) in the promoters of cytoprotective genes, including GSTM2, GCL, and GSS, which collectively maintain glutathione homeostasis. GSTM2 also interacts with MAP3K5 (ASK1), modulating JNK/AP-1 signaling and influencing apoptosis under stress conditions. Through these interactions, GSTM2 integrates cellular responses to xenobiotics and oxidative challenges.
In the HPV18-positive HeLa model, loss of GSTM2 is expected to compromise the detoxification capacity, increasing vulnerability to DNA damage and apoptosis induced by chemotherapeutic agents or environmental carcinogens. Given the established role of GSTM2 in drug metabolism, this knockout system is valuable for dissecting resistance mechanisms in cervical cancer. The interplay between GSTM2 and NFE2L2 signaling, which is often dysregulated in cancer, further highlights its relevance for studying adaptive responses to oncogenic stress. Moreover, the HeLa background enables concurrent analysis of HPV-related oncoprotein interactions with oxidative stress pathways.
These polyclonal GSTM2 knockout cells are suitable for a wide range of applications, including cancer drug resistance studies, xenobiotic metabolism assays, and oxidative stress research. Researchers can employ Western blotting and RT-qPCR to confirm GSTM2 loss, GST activity assays and cellular glutathione measurements to assess detoxification capacity, and comet assays to evaluate DNA damage. MTT assays can quantify chemosensitivity changes, while Nrf2 reporter assays probe upstream regulatory dynamics. Co-immunoprecipitation experiments can dissect GSTM2-ASK1 interactions. For further technical information or to explore customized applications, please contact Ascent Research.
